Insider buying last 90 days
$227Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 15 | Davidson Michael H. director, officer: Chief Executive Officer | Purchase | $227K |
From Form 4 filings, dated to when each was filed.
NASDAQ: NAMS
NewAmsterdam Pharma (NAMS) Stock Analysis & Forecast
Oct 12 close
$21.25−0.33 (−1.5%)
Gekko Brief
AI summaryOct 12 closeNewAmsterdam Pharma touched a 52-week low of $21.02 this week, extending a decline tied to concerns over its Phase III PREVAIL interim analysis. RBC Capital cut its price target on the stock to $42 from $50 on that trial risk, while maintaining an Outperform rating.
NAMS closed at $21.25, down 1.5%, and sits below both its 50-day average of $24.83 and 200-day average of $30.77, with the 50-day also below the 200-day. The GekkoIndex reading of 67.3 places the stock in the Accumulation zone. Shares trade 29.9% below Gekko Fair Value of $30.30.
The next earnings report is due 4 November 2026, before the open, 23 days away and inside a typical 20-trading-day holding window; the prior quarter showed an EPS beat with a 0.4% reaction. Over the last 90 days, there has been 1 open-market insider purchase valued at $226,500, alongside 2 billionaire holders and 1 trailblazer holder. Seasonally, the next 20 trading days have averaged +11% over 5 years, with gains in 3 of those years. Analyst sentiment remains uniformly positive, with 10 of 10 firms rating the stock a buy and a consensus target of $49.80. The combination of elevated historical volatility, a typical 20-day move of 9%, and an earnings date inside the window are worth noting.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
NewAmsterdam Pharma price vs fair value
Close $21.25200-day averageGekko Fair Value $30.30
NewAmsterdam Pharma quick facts
- Market cap
- $2.48B
- P/E ratio
- —
- Forward P/E
- 119.1
- EPS, TTM
- −$2.16
- Revenue, TTM
- $7.12M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.10
- Volume
- 812,288 avg 1.76M
- 1-year return
- −35.6%
- Typical daily move
- ±5.7%
- Typical 20-day move
- ±9%
- 50-day average
- $24.83
- 200-day average
- $30.77
- Next earnings
- Nov 4 before open
- Shares outstanding
- 116.9M
NewAmsterdam Pharma swing-trade checklist
NewAmsterdam Pharma scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $21.25 is below the 50-day ($24.83) and 200-day ($30.77) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
67.3, Accumulation
Reading 67.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
29.9% below
Price is 29.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+11.0% on average
From this point in the calendar, the next 20 trading days averaged +11% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
NewAmsterdam Pharma stock chart and price history
NewAmsterdam Pharma closed at $21.25 on Oct 12, 2026, −35.6% over the past year, inside a 52-week range of $20.91 to $42.21.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.8%
- 3 months
- −36.2%
- 6 months
- −41.4%
- 1 year
- −35.6%
The full NAMS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NAMS in Gekko
Follow NewAmsterdam Pharma through every session
Put NAMS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NAMS in GekkoFree for 7 days. No credit card required.
About NewAmsterdam Pharma
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on treatments for people with cardiometabolic disease. Its central program is obicetrapib, an oral, low-dose inhibitor of cholesteryl ester transfer protein, which the company is studying as a way to lower LDL cholesterol in patients at risk of cardiovascular problems. This compound is being tested both on its own and alongside ezetimibe across a range of clinical trials.
Beyond its cardiovascular work, the company is also examining obicetrapib as a potential treatment for Alzheimer's disease, with that application currently in a Phase 2a clinical trial. This gives NewAmsterdam Pharma two distinct areas of research built around the same underlying compound, one centered on heart health and the other on neurological disease, both still in clinical development rather than commercial use.
The company is headquartered in Naarden, in the Netherlands. Its shares are listed on the NASDAQ under the ticker NAMS.
- Listed
- NASDAQ
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Website
- newamsterdampharma.com
NewAmsterdam Pharma GekkoIndex: the smart money zone
NewAmsterdam Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.3, in the Accumulation zone, up 4.3 points over five sessions.
67.3Accumulation
Up 4.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 26 | +2.4% | +11.9% | ||
| Accumulation (current zone) | 268 | +1.9% | +3.7% | ||
| Neutral | 348 | −0.4% | −1.0% | ||
| Distribution | 33 | −1.1% | +2.3% | ||
| Selling | 7 | Too few readings yet | |||
Average NAMS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the NAMS price, zone by zone.Track NAMS in Gekko
Is NewAmsterdam Pharma stock overvalued? Gekko Fair Value
NewAmsterdam Pharma trades 29.9% below Gekko Fair Value of $30.30, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what NewAmsterdam Pharma shares are worth, recalculated every trading day.
$30.30
Gekko Fair Value, Oct 10, 2026
29.9% Undervalued
At the end of Aug 2026 the price was 42.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NAMS in Gekko
NewAmsterdam Pharma insider and Congress trading
Insiders filed 1 open-market purchase in NewAmsterdam Pharma worth $227K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NAMS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NAMS, plotted on the chart in Gekko.Open NAMS in Gekko
Hedge funds and billionaires quarter ended Dec 31
3of the funds Gekko tracks hold NAMS.
1added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
NewAmsterdam Pharma earnings: next date and track record
NewAmsterdam Pharma reports on Nov 4, 2026, before the open (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 23 days away
- EPS estimate
- −$0.49
- Revenue estimate
- $7.54M
3 of 8reports beat the EPS estimate
±9%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.52 est −$0.48 | $3.70M est $1.88M | +0.4% |
| May 7, 2026 | −$0.40 est −$0.46 | $3.04M est $1.74M | +25.0% |
| Feb 18, 2026 | −$0.63 est −$0.43 | $32K est $2.88M | −1.7% |
| Nov 5, 2025 | −$0.61 est −$0.38 | $348K est $5.31M | +1.4% |
| Aug 6, 2025 | −$0.15 est −$0.52 | $22.43M est $3.49M | +5.7% |
| May 8, 2025 | −$0.49 est −$0.45 | $3.22M est $1.46M | −2.9% |
| Feb 26, 2025 | −$0.95 est −$0.48 | $13.23M est $1.76M | +16.9% |
| Nov 6, 2024 | −$0.18 est −$0.48 | $32.52M est $1.87M | +18.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
NewAmsterdam Pharma stock forecast and analyst price targets
Analysts’ average 12-month price target for NewAmsterdam Pharma is $49.80, +134.4% from the last close, from 10 firms rating the stock in the last 90 days.
$49.80consensus 12-month target, +134.4% from the last close
Now $21.25Avg $49.80
Low $42High $60
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | RBC Capital | $42 | +97.6% |
| Oct 2 | Wells Fargo | $55 | +158.8% |
| Sep 29 | H.C. Wainwright | $52 | +144.7% |
| Sep 22 | Truist Financial | $57 | +168.2% |
| Sep 21 | BMO Capital | $58 | +172.9% |
+3.7%average 20-day move after past Accumulation readings
+11.0%average move over the next 20 trading days in the last 5 years
±5.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
NewAmsterdam Pharma seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, NewAmsterdam Pharma averaged +11.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 2 of 5 |
| Next 10 trading days | −2.3% | 2 of 5 |
| Next 15 trading days | +4.3% | 5 of 5 |
| Next 20 trading days | +11.0% | 3 of 5 |
| Next 30 trading days | +8.8% | 3 of 5 |
For scale, NAMS’s typical 20-trading-day move in either direction is about 9%.
NewAmsterdam Pharma market cap and key statistics
NewAmsterdam Pharma’s market cap is $2.48B and revenue of $7.12M over the last twelve months.
Valuation
- Market cap
- $2.48B
- Forward P/E
- 119.1
- EPS, TTM
- −$2.16
- Gekko Fair Value
- $30.30
Trading
- Volume
- 812,288
- Avg volume, 20 days
- 1.76M
- 52-week high
- $42.21
- 52-week low
- $20.91
- Shares outstanding
- 116.9M
Financials
- Revenue, TTM
- $7.12M
- Profit margin
- 0%
- Return on equity
- -36.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.10
- Typical daily move
- ±5.7%
- Typical 20-day move
- ±9%
NewAmsterdam Pharma stock news this week
2 headlines about NewAmsterdam Pharma from the past week, newest first, each linking to the publisher.
- Newamsterdam Pharma stock hits 52-week low at 21.02 USDInvesting.com, Oct 8
- RBC Capital cuts NewAmsterdam Pharma stock price target on trial riskInvesting.com, Oct 5
NewAmsterdam Pharma peers
NewAmsterdam Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Distribution | 25.9% above |
| CTASCintas | Neutral | 14.1% above |
| PYPLPayPal | Neutral | 0.8% below |
| XYZBlock | Neutral | 7.5% above |
| CPAYCorpay | Neutral | 17.5% below |
| FISVFiserv | Accumulation | 39.7% below |
A peer links to its own page where one exists.
NewAmsterdam Pharma stock FAQ
What is NewAmsterdam Pharma’s market cap?
NewAmsterdam Pharma’s market cap is $2.48B at the Oct 12, 2026 close of $21.25, with 116.9M shares outstanding.
What is the NewAmsterdam Pharma stock forecast?
The consensus analyst 12-month price target for NewAmsterdam Pharma is $49.80, +134.4% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is NewAmsterdam Pharma stock overvalued or undervalued?
On Gekko’s estimate NewAmsterdam Pharma is undervalued: the Oct 12, 2026 close of $21.25 is 29.9% below Gekko Fair Value of $30.30. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does NewAmsterdam Pharma report earnings next?
NewAmsterdam Pharma is expected to report on Nov 4, 2026, before the market opens (23 days away). Analysts expect earnings of −$0.49 per share on revenue of $7.54M. NewAmsterdam Pharma beat the earnings estimate in 3 of its last 8 reports, moving 9% on average across the report.
What is NewAmsterdam Pharma’s 52-week high and low?
NewAmsterdam Pharma’s 52-week high is $42.21 and its 52-week low is $20.91; it closed at $21.25 on Oct 12, 2026, −35.6% over the past year.
Is NewAmsterdam Pharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See NewAmsterdam Pharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.